The size of the APAC radiofrequency ablation devices market is predicted to grow at a CAGR of 10.34% from 2023 to 2028 and worth USD 0.39 billion by 2028 from USD 0.24 billion in 2023.
Radiofrequency ablation is a minimally invasive procedure suitable for heart disease, cancer, and pain management patients, and it is increasingly preferred due to its high efficiency, ease of use, and safety. However, pain leads to severe complications if proper care or treatment is not taken long. The lower risk of complications offered by this mode of therapy has supported the adoption of RF ablation devices. The Radiofrequency technique is very effective for surgical oncology with rapid recovery and more minor side effects for cancer patients. Although older people benefit significantly from these procedures, they also have a higher prevalence of various cancers. In 2020, the old-age group in Egypt was recorded at 8.98%, indicating that around nine people in the 65+ age group per 100 working-age population in the region. While the population from 2020 showed over 59.75 million in South Africa. In this data, about 30.58 million were women, while 5.45 million people were males.
Factors such as high availability, quick results, ease of access, increased awareness, and cost-effectiveness, have resulted in the widespread adoption of radiofrequency ablation devices as the primary treatment option. This is likely to increase the demand for pain management in arthritis, osteoporosis, and myalgia. In addition, the high side effects and lower effectiveness of alternative pain relief treatments and procedures, such as acupuncture, chiropractic, and acupressure, have led to an increase in the uptake of radiofrequency ablation technology.
However, even if the radiofrequency is a beneficial procedure, it is only for a highly selective group of patients eligible for the procedure, which is anticipated to limit the growth of the MEA radiofrequency ablation devices market.
This research report on the Middle East and Africa radiofrequency medical devices market has been segmented and sub-segmented into the following categories.
Cardiology & Cardiac Rhythm Management
rest of GCC countries
rest of MEA
Geographically, the Middle East is anticipated to hold a significant share of the MEA market during the forecast period due to many patient bases and improvements in the healthcare industry. In 2020, the regional market in Saudi Arabia dominated the MEA market with 35%, and this region is predicted to continue its dominance during the forecast period. The main factors contributing to regional growth are the high prevalence of cancer, rich investments supporting many technological advancements. This large population suffers from chronic diseases and government support for quality health care. The KSA population representing the aging group over age 60 is reported to increase from 3.11 % in 2010 to 10.55 % by 2035. The prevalence of osteoarthritis increases with age, reaching about 30.99% in those aged 46 to 55 years old and 60.78% in the 66 to 75 years old group.
South Africa is anticipated to post the fastest CAGR during the forecast period. The introduction of advanced technologies, increasing disposable income, large senior population, rapidly growing chronic disease rate, and developing market will drive the market in this region. Osteoarthritis was the most common form of arthritis, and in urban areas, it was 55.5% in South Africa and the rural regions all in South Africa 82.89% in adults over 65.
KEY MARKET PLAYERS:
Companies playing a pivotal role in the MEA radiofrequency ablation devices market profiled in this report are AngioDynamics, Ethicon, ZenoMed, AtriCure, Inc, Baren-Boym, Huaian Aofu Surgical Instruments Co., Ltd, MedSphere, and Medtronic.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com